• 10 Biggest Antidepressant Drug Companies In 2017
    Insider Monkey17 hours ago

    10 Biggest Antidepressant Drug Companies In 2017

    The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]

  • Benzinga2 days ago

    ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

    The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta.  This year's meeting was ...

  • Glaxo's Nucala Label Expansion Application Gets FDA Approval
    Zacks2 days ago

    Glaxo's Nucala Label Expansion Application Gets FDA Approval

    GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.

  • Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer
    Bloomberg4 days ago

    Glaxo's New Pharma Head Looks to Move Fast, Especially in Cancer

    GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, signaled it will look to speed development of an experimental cancer treatment as part of its ambition to expand in oncology just two years after selling ...

  • American City Business Journals7 days ago

    GlaxoSmithKline's Rockville chief lays out priorities for 2018

    British pharmaceutical giant GlaxoSmithKline PLC said it finally has a full team in place at its vaccine hub in Rockville and is ready to take on some of the region's most well-known biotech competitors with part of its product lineup. This next year, officials said, will be about taking a leadership position in new vaccine technologies and advancing its priority projects, including a vaccine for shingles as well its vaccine candidate for respiratory syncytial virus, a common respiratory virus that often attacks infants and the elderly — and a key disease target already for major players such as MedImmune and Novavax Inc. "It's really getting down to business and doing the work," said Rip Ballou, vice president and head of GSK's (GSK) Global Vaccines U.S. Research and Development Center in Rockville.

  • Capital Cube8 days ago

    ETFs with exposure to GlaxoSmithKline Plc : December 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to GlaxoSmithKline Plc Here are 5 ETFs with the largest exposure to GSK-GB. Comparing the performance and risk of GlaxoSmithKline Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Reuters8 days ago

    Companies prepare for disorderly Brexit as talks stall

    Big companies are stepping up their plans in case Britain crashes out of the European Union without a deal as Prime Minister Theresa May struggles to get talks back on track after a major setback. Britain is aiming to agree with the EU on Dec. 14 to move the Brexit talks on to the second phase. Senior executives in the financial services sector, which accounts for about 12 percent of the economy, told Reuters May's efforts to secure a transition deal had come too late and they had no choice but to start restructuring.

  • Barrons.com9 days ago

    Glaxo Who? Why Gilead's HIV Drug Could Be the 'Greatest of All Time'

    Shares of Gilead Sciences (GILD) are rising Wednesday, helped by a bullish note from Credit Suisse, which argues that its HIV treatment Bictegravir could be a launch that will become "the greatest ...

  • Market Realist9 days ago

    GlaxoSmithKline’s Vaccines Business in 3Q17

    GlaxoSmithKline’s (GSK) Vaccines business reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.

  • GSK, other drugmakers bet on post-Brexit UK science
    Reuters9 days ago

    GSK, other drugmakers bet on post-Brexit UK science

    Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit. The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union. Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.

  • Reuters9 days ago

    PRESS DIGEST- Financial Times - Dec 6

    The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines * Deutsche Bank sends Trump financial details to Mueller ...

  • Drug Companies From Glaxo to J&J Pledge to Make U.K. Investments
    Bloomberg9 days ago

    Drug Companies From Glaxo to J&J Pledge to Make U.K. Investments

    GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. and AstraZeneca Plc are among more than two dozen global pharmaceutical companies pledging to invest funds in the U.K. as part of a multi-billion-pound ...

  • GlaxoSmithKline Plc :GSK-GB: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
    Capital Cube9 days ago

    GlaxoSmithKline Plc :GSK-GB: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017

    Categories: Yahoo FinanceGet free summary analysis GlaxoSmithKline Plc reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of GlaxoSmithKline Plc – AstraZeneca PLC and Shire PLC (AZN-GB and SHP-GB) that have also reported for this period. Highlights Summary numbers: Revenues of GBP 7843 million, Net Earnings of ... Read more (Read more...)

  • Australian watchdog takes GlaxoSmithKline, Novartis units to court
    Reuters9 days ago

    Australian watchdog takes GlaxoSmithKline, Novartis units to court

    The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are "identically formulated". "We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said.

  • GlaxoSmithKline and the Dividend Mirage
    GuruFocus.com9 days ago

    GlaxoSmithKline and the Dividend Mirage

    The closer you get, the more ephemeral the company's 6% dividend yield looks

  • The Wall Street Journal9 days ago

    Glaxo's Karenann Terrell Enlists AI in Understanding HIV Patients

    GlaxoSmithKline is using artificial intelligence to learn why certain HIV patients drop out of treatment. "The only clues that exist are in unstructured types of data," such as doctor's notes, ...

  • Market Realist10 days ago

    GlaxoSmithKline’s Global Pharmaceuticals Business in 3Q17

    The Global Pharmaceuticals business reported revenues of 3.1 billion pounds during 3Q17.

  • Investors Are Undervaluing GlaxoSmithKline plc (LSE:GSK) By 32.79%, Here Is My Intrinsic Value Calculation
    Simply Wall St.10 days ago

    Investors Are Undervaluing GlaxoSmithKline plc (LSE:GSK) By 32.79%, Here Is My Intrinsic Value Calculation

    Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of GlaxoSmithKline plc (LSE:GSK) as an investment opportunity. If you wantRead More...

  • Market Realist11 days ago

    GlaxoSmithKline’s Business Segments in 3Q17

    GlaxoSmithKline’s (GSK) Vaccines segment reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.

  • Market Realist11 days ago

    GlaxoSmithKline’s Quarterly Revenues for 3Q17

    GlaxoSmithKline's (GSK) 3Q17 revenues of ~7.8 billion pounds represented 4.0% growth compared to its 3Q16 revenues of ~7.5 billion pounds.

  • Market Realist11 days ago

    GlaxoSmithKline’s Valuation in November 2017

    In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.

  • Is a Dividend Cut Coming From GlaxoSmithKline plc?
    Motley Fool13 days ago

    Is a Dividend Cut Coming From GlaxoSmithKline plc?

    Is the company's rich yield an opportunity for investors, or a warning of trouble ahead?

  • 3 Drug/Biotech Stocks in Focus on World AIDS Day
    Zacks13 days ago

    3 Drug/Biotech Stocks in Focus on World AIDS Day

    On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.

  • Market Realist13 days ago

    Gauging Novartis’s Valuation This November

    Novartis saw revenues of ~$12.4 billion and EPS of $1.29 for 3Q17, which represents a 2% YoY rise, compared with its revenues of ~$12.1 billion in 3Q16.

  • Reuters14 days ago

    FTSE falls in broad risk-off move as Trump worries resurface

    The FTSE fell on Friday at the end of a choppy session that saw Britain's top-share index accelerate losses and join a global risk-off move following reports in the United States that raised new worries over the stability of Donald Trump's administration. The FTSE fell 0.4 percent, having earlier gained as much as 0.4 percent thanks to a pull back in the pound that helped it recover from the losses seen in morning trade. ABC News reported that former U.S. national security adviser Michael Flynn was prepared to testify that Trump directed him to make contact with Russians when he was a presidential candidate.